{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogens&page=18", "query": { "condition": "Estrogens", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 754, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogens&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogens&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T04:00:47.435Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02202746", "title": "A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "MBC", "HER2 Positive", "HER2", "Estrogen Receptor Positive", "ER", "Triple Negative" ], "interventions": [ { "name": "Lucitanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clovis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2014-09-09", "completion_date": "2017-01-18", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 33, "location_summary": "Sedona, Arizona • Bakersfield, California • Fullerton, California + 25 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02202746" }, { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" }, { "nct_id": "NCT00154180", "title": "Kronos Early Estrogen Prevention Study (KEEPS)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Menopause", "Arteriosclerosis" ], "interventions": [ { "name": "Conjugated equine estrogens 0.45 mg/day", "type": "DRUG" }, { "name": "Transdermal estradiol, 50 mcg/day", "type": "DRUG" }, { "name": "Micronized progesterone, 200 mg/day x 12 d/month", "type": "DRUG" }, { "name": "CEE , progesterone, estradiol patch or placebo for each", "type": "DRUG" }, { "name": "CEE, progesterone, transdermal patch or the placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kronos Longevity Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Years", "maximum_age": "58 Years", "sex": "FEMALE", "summary": "42 Years to 58 Years · Female only" }, "enrollment_count": 728, "start_date": "2005-09", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2009-09-14", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 9, "location_summary": "Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00154180" }, { "nct_id": "NCT03455270", "title": "G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Ductal, Breast", "Breast Cancer Female", "Breast Neoplasm", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "G1T48", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 107, "start_date": "2018-05-09", "completion_date": "2022-09-29", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 6, "location_summary": "Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03455270" }, { "nct_id": "NCT00056082", "title": "Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 110, "start_date": "2003-01", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 3, "location_summary": "Chicago, Illinois • Kansas City, Kansas • Oklahoma City, Oklahoma", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056082" }, { "nct_id": "NCT02120469", "title": "Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor-negative", "Stage IV Breast Cancer", "Triple-negative Breast Carcinoma" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "eribulin mesylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2014-11-17", "completion_date": "2020-03-03", "has_results": true, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 3, "location_summary": "Duarte, California • Rancho Cucamonga, California • South Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120469" }, { "nct_id": "NCT03633331", "title": "Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "HER2/Neu Negative", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 93, "start_date": "2018-08-15", "completion_date": "2026-02-27", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 447, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Arroyo Grande, California + 303 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03633331" }, { "nct_id": "NCT00010829", "title": "Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cardiovascular Diseases", "Osteoporosis", "Breast Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "American Heart Association Step 1 diet", "type": "BEHAVIORAL" }, { "name": "American Heart Association Step 2 diet + 10 g/day flax seed", "type": "BEHAVIORAL" }, { "name": "Macrobiotic dietary intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Center for Complementary and Integrative Health (NCCIH)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "72 Years", "sex": "FEMALE", "summary": "50 Years to 72 Years · Female only" }, "enrollment_count": null, "start_date": "2001-01", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2006-08-18", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00010829" }, { "nct_id": "NCT03718494", "title": "Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer Dementia" ], "interventions": [ { "name": "Brain Magnetic Resonance Imaging (MRI)", "type": "DIAGNOSTIC_TEST" }, { "name": "F-18 Florbetapir Positron Emission Tomography (PET) Imaging", "type": "DIAGNOSTIC_TEST" }, { "name": "F-18 AV-1451 Positron Emission Tomography (PET) Imaging", "type": "DIAGNOSTIC_TEST" }, { "name": "Neuropsychological Testing", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "49 Years", "maximum_age": "72 Years", "sex": "FEMALE", "summary": "49 Years to 72 Years · Female only" }, "enrollment_count": 299, "start_date": "2019-05-22", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2023-07-17", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 6, "location_summary": "Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03718494" }, { "nct_id": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER-2 Positive Breast Cancer", "Estrogen Receptor Positive Breast Cancer" ], "interventions": [ { "name": "palbociclib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "pertuzumab", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2017-06-21", "completion_date": "2030-12-31", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-30T04:00:47.435Z", "location_count": 35, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02947685" } ] }